Region Hovedstaden

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease1 trial
• Childhood cancers1 trial
• Dilated cardiomyopathy1 trial
• Follicular lymphoma1 trial
• Huntington's disease1 trial
• Idiopathic pulmonary fibrosis1 trial
• Mantle cell lymphoma1 trial
• Metastatic breast cancer1 trial
• Multiple myeloma1 trial
• Myasthenia gravis1 trial
• Osteoporosis1 trial

Phase

• Phase 24 trials
• Phase 34 trials
• Phase 1/21 trial

Status

• Not yet recruiting6 trials
• Recruiting3 trials

Lead sponsor

• AstraZeneca AB2 trials
• Aurinia Pharmaceuticals Inc.1 trial
• Celcuity Inc1 trial
• Hoffmann-La Roche1 trial
• Kardigan Inc.1 trial
• and 3 more

Running trials

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  A Phase 2, open-label trial to investigate the long-term safety of VO659 administered intrathecally in participants with Huntington’s disease and spinocerebellar ataxia type 1 and 3

  2026-526408-60-00· Phase 2· Vico Therapeutics B.V.· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

  2026-526139-20-00· Phase 3· Kardigan Inc.· Source

• Recruiting

  A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

  NCT07700758· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· AstraZeneca AB· Source

• Not yet recruiting

  Zoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma

  2026-527220-27-00· Phase 3· Region Nordjylland· Source

• Recruiting

  A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis

  2025-525127-27-00· Phase 1/2· Aurinia Pharmaceuticals Inc.· Source

• Recruiting

  Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  NCT06757634· Phase 3· Celcuity Inc· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting
• Childhood cancers1 recruiting
• Dilated cardiomyopathy1 recruiting
• Follicular lymphoma1 recruiting
• Huntington's disease1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myasthenia gravis1 recruiting
• Osteoporosis1 recruiting